Vanguard Group Inc. Sells 9,926 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Vanguard Group Inc. trimmed its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 0.0% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 21,068,261 shares of the medical research company’s stock after selling 9,926 shares during the quarter. Vanguard Group Inc. owned approximately 0.12% of IQVIA worth $5,327,953,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also bought and sold shares of IQV. Norges Bank bought a new stake in shares of IQVIA in the 4th quarter worth approximately $383,705,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main grew its position in shares of IQVIA by 339.6% in the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 2,067,195 shares of the medical research company’s stock worth $478,308,000 after buying an additional 1,597,003 shares during the last quarter. Morningstar Investment Services LLC grew its position in shares of IQVIA by 96.9% in the 4th quarter. Morningstar Investment Services LLC now owns 1,231,916 shares of the medical research company’s stock worth $286,704,000 after buying an additional 606,333 shares during the last quarter. Capital Research Global Investors grew its position in shares of IQVIA by 42.2% in the 4th quarter. Capital Research Global Investors now owns 1,995,269 shares of the medical research company’s stock worth $461,675,000 after buying an additional 592,372 shares during the last quarter. Finally, Cadian Capital Management LP bought a new stake in shares of IQVIA in the 4th quarter worth approximately $70,108,000. 89.62% of the stock is currently owned by institutional investors.

IQVIA Stock Down 0.1 %

Shares of IQVIA stock traded down $0.28 on Friday, reaching $224.57. The company’s stock had a trading volume of 1,093,584 shares, compared to its average volume of 1,339,091. The company has a market capitalization of $40.92 billion, a price-to-earnings ratio of 30.68, a P/E/G ratio of 2.05 and a beta of 1.49. The firm’s fifty day simple moving average is $219.54 and its two-hundred day simple moving average is $228.85. IQVIA Holdings Inc. has a 52 week low of $167.42 and a 52 week high of $261.73. The company has a quick ratio of 0.88, a current ratio of 0.88 and a debt-to-equity ratio of 2.02.

IQVIA (NYSE:IQV) last posted its earnings results on Thursday, May 2nd. The medical research company reported $2.30 EPS for the quarter, topping analysts’ consensus estimates of $2.19 by $0.11. The business had revenue of $3.74 billion during the quarter, compared to analyst estimates of $3.69 billion. IQVIA had a return on equity of 29.17% and a net margin of 9.01%. Equities analysts anticipate that IQVIA Holdings Inc. will post 10.11 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. Barclays lowered their target price on IQVIA from $275.00 to $255.00 and set an “overweight” rating for the company in a research note on Friday, June 28th. Robert W. Baird lowered their target price on IQVIA from $241.00 to $235.00 and set a “neutral” rating for the company in a research note on Wednesday, July 10th. StockNews.com upgraded IQVIA from a “hold” rating to a “buy” rating in a research note on Monday, July 15th. Truist Financial lowered their target price on IQVIA from $297.00 to $292.00 and set a “buy” rating for the company in a research note on Friday, May 3rd. Finally, Evercore ISI lowered their target price on IQVIA from $250.00 to $230.00 and set an “outperform” rating for the company in a research note on Tuesday, July 9th. Three equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. According to MarketBeat, IQVIA currently has a consensus rating of “Moderate Buy” and a consensus target price of $255.73.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.